MORAb-004 (monoclonal antibody)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma
Conditions
Metastatic Melanoma
Trial Timeline
May 16, 2011 → Apr 10, 2020
NCT ID
NCT01335009About MORAb-004 (monoclonal antibody)
MORAb-004 (monoclonal antibody) is a phase 2 stage product being developed by Eisai for Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01335009. Target conditions include Metastatic Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01335009 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Melanoma